1 / 5

Global Parkinson’s Disease Market

Biopharma giants, medtech pioneers, and AI startups are reshaping the therapeutic pipelineu2014targeting disease modification, enhancing patient quality of life, and closing access gaps across geographies.<br>The Parkinson's market is not just growingu2014itu2019s transforming. And the momentum is just getting started.

Insights10
Télécharger la présentation

Global Parkinson’s Disease Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GLOBAL PARKINSON’S DISEASE MARKET

  2. MARKET SIZE The global Parkinson’s disease therapeutics market is projected to reach $15.25 billion by 2033, growing at a 9.1% CAGR. This growth is driven by rising disease prevalence, innovations in gene therapy and diagnostics, and increasing investments from pharma and biotech companies. Market Size (USD Bn) 15.25 13.98 9.1% CAGR 12.82 11.75 10.77 9.87 9.05 8.29 7.6 2025 2026 2027 2028 2029 2030 2031 2032 2033

  3. MARKET SEGMENTATION RECENT DEVELOPMENTS According to Therapy Type March 2025: Medtronic’s BrainSense™ Adaptive DBS and Electrode Identifier received FDA approval, improving precision in Parkinson’s treatment 11% February 2025: AskBio’s gene therapy AB-1005 got RMAT designation from the FDA to fast-track development February 2025: FDA approved Supernus’ Onapgo, a drug-device delivering continuous apomorphine under the skin for Parkinson’s motor symptoms 89% January 2025: WEHI revealed the structure of PINK1, a Parkinson’s-linked protein, unlocking potential for targeted therapies Pharmacological (drug-based treatments) Non-pharmacological (surgical procedures, deep brain stimulation)

  4. MARKET DYNAMICS: DRIVERS AND RESTRAINTS Technological advancements in gene therapy, stem cell research, and drug delivery are expanding treatment options Medication side effects reduce patient compliance and treatment satisfaction Improved diagnostic techniques, including imaging and biomarkers, enable earlier intervention and better patient outcomes Slow clinical trial progression and challenges in advancing therapies limit market growth Drivers Restraints Increased R&D investment by pharmaceutical companies and government bodies is accelerating drug discovery High treatment costs and restricted access in developing regions hinder market expansion

  5. KEY PLAYERS

More Related